Drug Profile
Research programme: immunotherapy - sigma-tau
Alternative Names: Pentraxin 3; PTX 3Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator sigma-tau SpA
- Class Proteins
- Mechanism of Action Complement activation stimulants; Cytokine stimulants; Cytomegalovirus replication inhibitors; Transcription factor stimulants; Viral fusion protein inhibitors; Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Aspergillosis; Cytomegalovirus infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Aspergillosis in Italy (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cytomegalovirus infections(Prevention) in Italy (Parenteral)
- 04 Jun 2008 Development of PTX3 is ongoing